The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study.
BACKGROUND
Treatment for hidradenitis suppurativa is often empiric and inadequate, and determining which patients will respond is difficult.


OBJECTIVE
We sought to determine which patient factors are associated with a positive response to first-line medical therapy.


METHODS
A single-center retrospective cohort study of all patients with hidradenitis suppurativa seen between January 1, 1992, and October 1, 2014, was conducted. Response to first-line medical therapy (oral/topical antibiotics, intralesional corticosteroids, and topical washes) was examined at follow-up within 6 months of initiating therapy. A multivariate binary logistic regression model was built examining response to treatment and the interplay of patient factors and treatment initiated.


RESULTS
In all, 198 patients were included in the final model. Nonsmokers (odds ratio 2.634, 95% confidence interval 1.301-5.332, P = .007) and older individuals (odds ratio 1.046 for each additional year, 95% confidence interval 1.020-1.072, P < .001) were more likely to have improvement at follow-up. In addition, current smokers differed significantly from nonsmokers in several regards.


CONCLUSIONS
The retrospective nature of this study is a limitation, as is relying on classification of disease severity from physical examination findings in some patients.


CONCLUSIONS
The results of this study suggest that clinicians may be able to more accurately predict which patients with hidradenitis suppurativa will respond to first-line medical therapy, and which patients may require therapy escalation.
Washington University School of Medicine, St Louis, Missouri. Electronic address: manadkat@dom.wustl.edu.
George
G
Denny
Division of Dermatology, St Louis, Missouri; Washington University School of Medicine, St Louis, Missouri.
Milan J
MJ
Anadkat
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012907:Smoking; D016896:Treatment Outcome; D055815:Young Adult
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local
acne inversa; first-line treatment; hidradenitis suppurativa; increased age; medical therapy; patient response; smoking
Eur J Pharmacol. 2011 Dec 15;672(1-3):1-8
21930119
J Am Acad Dermatol. 2009 Jul;61(1):51-7
19406505
J Invest Dermatol. 2013 Jun;133(6):1506-11
23235532
J Biomed Inform. 2009 Apr;42(2):377-81
18929686
Br J Dermatol. 2010 Jun;162(6):1261-8
20184581
Autoimmune Dis. 2012;2012:251730
22195277
Dermatoendocrinol. 2010 Jan;2(1):9-16
21547142
Autoimmun Rev. 2012 Aug;11(10):754-65
22387972
J Am Acad Dermatol. 2008 Oct;59(4):596-601
18674845
J Am Acad Dermatol. 2014 Dec;71(6):1144-50
25440440
J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):191-4
8708018
J Natl Cancer Inst. 2014 Oct 01;106(11):null
25274579
Br J Dermatol. 2009 Oct;161(4):831-9
19438453
Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):245-8
2936421
N Engl J Med. 2012 Jan 12;366(2):158-64
22236226
J Invest Dermatol. 2013 Jan;133(1):97-103
22931916
Br J Dermatol. 1986 Sep;115(3):263-8
2944534
Exp Dermatol. 2012 Oct;21(10):735-9
22882284
J Eur Acad Dermatol Venereol. 2000 Sep;14(5):389-92
11305381
J Gerontol B Psychol Sci Soc Sci. 2009 Nov;64 Suppl 1:i94-105
19204073
J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3
19293006
Acta Dermatovenerol Alp Pannonica Adriat. 2009 Dec;18(4):165-72
20043054
Dermatology. 1999;198(3):261-4
10393449